Neuropacs Parkinsonian Syndromes
Overview
Neuropacs Parkinsonian Syndromes(by Neuropacs) is an AI-powered, prescription-only software application designed to assist in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndromes, specifically multiple system atrophy Parkinsonian variant (MSAp) and progressive supranuclear palsy (PSP).
The software is intended for use by neurologists and neuroradiologistsevaluating patients aged 40 years and older who present with parkinsonian symptoms. It is designed as an adjunctive diagnostic aid to provide supplemental information alongside standard neurological assessments, rather than as a standalone diagnostic tool.
Clinical Workflow Integration:
- The platform operates via a secure, cloud-based workflow.
- It utilizes standard, non-invasive diffusion MRI sequences acquired on 3 Tesla clinical MRI systems from major manufacturers, including Siemens, GE Healthcare, and Philips.
- The system processes the imaging data using a validated free-water imaging (FWI) model and machine learning algorithms to analyze degenerative brain patterns.
- It automatically generates a classification report detailing the degenerative patterns associated with MSAp and PSP to support clinical decision-making and patient stratification.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven diagnostics trained on harmonized multi-site data
- Exclusive, patented Free-Water Imaging (FWI) technology
- Up to 96% accuracy in distinguishing PD from MSAp and PSP
- Quantitative disease insights (measures severity, rate, and state of degeneration)
- Next-level sensitivity for detecting subtle microstructural changes
- Cloud-based workflow for seamless integration
- Supports clinical decision-making and clinical trial outcomes
- Analyzes patient-specific diffusion MRI data
- Compatible with standard diffusion MRI sequences on 3T MRI systems (Siemens, GE Healthcare, Philips)
- Generates classification reports for Parkinsonian syndromes
Use Cases
- Differentiating Parkinson's disease from atypical parkinsonian syndromes (MSAp, PSP)
- Improving diagnostic accuracy in neurodegenerative diseases
- Patient stratification for neurodegenerative clinical trials
- Measuring quantitative progression markers for efficacy assessment in trials
- Optimizing clinical endpoint achievement in trials
- Supporting neuroradiologists and neurologists in clinical assessment
What Physicians Need to Know
Neuropacs offers high precision in distinguishing Parkinsonian Syndromes, with up to 96% accuracy in differentiating PD from MSAp and PSP. Its AI-powered, imaging-enabled software provides quantitative disease insights, measuring severity, rate, and state of degeneration. The platform detects subtle microstructural changes beyond what volumetric imaging sees, which can be crucial for early disease detection and monitoring. It is backed by extensive research and validated across numerous MRI scans and clinical trials, providing academic rigor and real-world applicability.
The platform is delivered via a secure cloud-based workflow and is designed for seamless integration into existing imaging workflows.
Details
| Category | Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neuropacs Parkinsonian Syndromes
Videos
Product demos, reviews, and walkthroughs for Neuropacs Parkinsonian Syndromes.
How Neuropacs helps neurologists differentiate types of Parkinsonism
neuropacs



